Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05108779
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections
Phase 2
- Conditions
- Complicated Urinary Tract InfectionAcute Pyelonephritis
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05060419
Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD)
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: FL058 1000mg and Meropenem 2000mg （ IV 120min）Drug: FL058 1000mg and Meropenem 2000mg （ IV 180min）Drug: FL058 1000mg（ IV 120min）Drug: FL058 500mg and Meropenem 1000mg（ IV 120min）Drug: FL058 2000mg and Meropenem 2000mg（ IV 180min）Drug: FL058 Placebo and Meropenem 2000m（ IV 180min）Drug: FL058 Placebo and Meropenem 1000mg（ IV 120min）Drug: FL058 Placebo （ IV 120min）Drug: FL058 Placebo and Meropenem 2000m（ IV 120min）Drug: FL058 Placebo and Meropenem 2000mg（ IV 180min）Drug: FL058 1000mg and Meropenem 1000mg （ IV 120min）Drug: FL058 Placebo and Meropenem 1000mg （ IV 120min）
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05058105
- Locations
- 🇨🇳
Huashan Hospital affiliated to Fudan University, Shanghai, China
Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD)
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT05058118
- Locations
- 🇨🇳
Huashan Hospital affiliated to Fudan University, Shanghai, China
Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD/MAD)
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05055687
- Locations
- 🇨🇳
Huashan Hospital affiliated to Fudan University, Shanghai, China
CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05052567
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT04954456
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
Phase 2
Terminated
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT04864782
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangzhou, China
Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer
Phase 3
- Conditions
- Non-Muscle Invasive Bladder Cancer
- Interventions
- Drug: VB4-845 Injection
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT04859751
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT04651036
- Locations
- 🇩🇪
Parexel International GmbH Early Phase Clinical Unit Berlin, Berlin, Germany
🇬🇧Parexel Early Phase Clinical Unit, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath